Both in BPH and PCa surgical patients, the percentage of TNFRII-positive cells with weak immunoexpression was significantly lower (p < 0.001), and TNFRII-positive cells with moderate immunoexpression were significantly higher (p = 0.020, p = 0.021, respectively) vs. the PCa palliative group. The gene discussed is TNFRSF1B; the disease is benign prostatic hyperplasia.